Lung Cancer Dispatch
4.5K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Astrazeneca’s Medimmune Presents Encouraging Immunotherapy Data at ASCO 2014

"MedImmune, the global biologics research and development arm of AstraZeneca, presented results today from its novel investigational immunotherapy portfolio, focusing on MEDI4736, at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting.  Overall, studies demonstrated durable clinical activity and tolerability for MEDI4736 across a range of tumor types.


"This announcement follows the recent progression of the first Phase III study for MEDI4736, an investigational, engineered, human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumors avoid detection by the immune system. It is believed that by targeting PD-L1, MEDI4736 may block this ligand from sending out signals to T-cells to ‘ignore’ tumor cells, thereby countering cancer’s immune-evading tactics.


Editor's note: Immunotherapy treatments that boost a patient's own immune system to fight cancer are a promising area of cancer research. A new immunotherapy drug called MEDI4736 is being tested in volunteer patients with different cancer types, and has shown good results for some patients with advanced non-small cell lung cancer (NSCLC).

Cancer Commons's insight:

MedImmune  |  Jun 3, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

AstraZeneca Launches Phase 3 Study of NSCLC Immunotherapy

AstraZeneca Launches Phase 3 Study of NSCLC Immunotherapy | Lung Cancer Dispatch | Scoop.it

"On the heels of rebuking merger offers from Pfizer, AstraZeneca announced in a press release it is moving forward with the phase 3 PACIFIC trial of a lung cancer immunotherapy drug.


"The drug, MEDI4736, is a human monoclonal antibody directed against programmed death ligand 1 (PD-L1). The drug, still in development, targets the PD-L1/PD-1 pathway for the treatment of non–small cell lung cancer (NSCLC) by blocking signals which allow PD-L1 to escape detection by the immune system."


Editor's note: MEDI4736 is an immunotherapy drug that is meant to boost a patient's own immune system to fight cancer. Learn more about immunotherapy and clinical trials here.

Cancer Commons's insight:

Healio  |  May 9, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

AstraZeneca Seeking to Get Cancer Drugs to Patients Early

AstraZeneca Seeking to Get Cancer Drugs to Patients Early | Lung Cancer Dispatch | Scoop.it

"British patients could benefit from AstraZeneca's promising new cancer drugs well before they complete clinical testing, the Telegraph can reveal.


"Pascal Soriot, chief executive, told the Telegraph he was looking to make two of Astra's most eye-catching cancer drugs widely available to patients as soon as possible.


"Britain's recently launched early access to medicines scheme, which aims to get drugs to patients years earlier than the normal regulatory process allows, is among the programmes in Mr Soriot's sights. The US, France and Japan have also established pathways to fast-track promising new drugs to patients ahead of final regulatory approval."

Cancer Commons's insight:

The Telegraph  |  Jun 2, 2014

more...
No comment yet.